CHRS
Coherus Oncology Sets Sights on $33 Billion Market Opportunity
Coherus Oncology has announced a strong start to the year, with the company's Q1 2026 earnings call revealing a clear strategy for growth and expansion. At the helm of this effort is LOQTORZI, a next-generation PD-1 inhibitor that is set to play a crucial role in the company&